posted on 2012-12-21, 00:00authored byGoetz Parsiegla, Christophe Noguere, Lydia Santell, Robert A. Lazarus, Yves Bourne
Recombinant human DNase I (Pulmozyme, dornase alfa) is
used for
the treatment of cystic fibrosis where it improves lung function and
reduces the number of exacerbations. The physiological mechanism of
action is thought to involve the reduction of the viscoelasticity
of cystic fibrosis sputum by hydrolyzing high concentrations of DNA
into low-molecular mass fragments. Here we describe the 1.95 Å
resolution crystal structure of recombinant human DNase I (rhDNase
I) in complex with magnesium and phosphate ions, both bound in the
active site. Complementary mutagenesis data of rhDNase I coupled to
a comprehensive structural analysis of the DNase I-like superfamily
argue for the key catalytic role of Asn7, which is invariant among
mammalian DNase I enzymes and members of this superfamily, through
stabilization of the magnesium ion coordination sphere. Overall, our
combined structural and mutagenesis data suggest the occurrence of
a magnesium-assisted pentavalent phosphate transition state in human
DNase I during catalysis, where Asp168 may play a key role as a general
catalytic base.